RE:blackrockGiven everything we know, I'm speculating CRX $60 / CXRX $46 short term, easy. Here's why. Bashers, if you still aren't ignoring me, skip the pain, move to the next message now.
Short term is easy. Long term will have to be re-evaluated after short term but there is nothing negative once the debt is paid off. The financials look great.
The debt is a red herring promoted by the short thesis. The noise is getting old. The atttacks on the CEO are baseless. 100% fabrication from my perspective. If not, point me to facts.
The last fact is the CEO bought, on the opn market $1M worth of shares late last year at much higher prices. Look it up yourself. That's the value of this company and the latest quarter validated this, that is why we saw double digit gains Friday. And volume shot right up.
The long thesis, backed with solid fundamentals and positive technical analysis indicators. is the winning strategy here at these prices. No need to be a trader to enjoy high gains.
Could there be a bliind side? Yes but noody has presented any valid reg flags currently.
Big money will flow in and the shorts will lose total control, if they haven't already. The volume on CXRX was much higher on Friday so they are buying, not selling right now. Short ratio volumes are down below 50% so we have more covering that shorting.
Bashers have no valid arguments. It's too obvious isn't it?
The debt is getting repad, no issues.
The elephant in the room is bashing shorts and banksters know that Concordia is an acquisition based company. It seems Concordia is positioning the cash from Amco for a small upcoming acquisition as indicated in a recent prior conference call.
The latest messages I've heard was the next moves would benefit shareholders and I buy that. I give 1% credibility to the shorts for the debt component and it's low because they overplayed that card.
Now they are doing the "it's the CEO's fault", which it isn't.
Maybe give the short thesis 5% for "poor communication to shareholders". That has some validity. The investor web site is poor in that important info is buried and a lot of material is not curent. .They sould update the presentation slides with current numbers etc. They should also have the top 10 items on the main page with ability to drill down to the current menu structure. Too hard to find things, sedar is the primary source but added info via IR web sites is always pro-investor.
Investors are obviously nervous here. The more communication the better.
At $33, this is probably one of the better positioned health recovery stock on the TSE? Anyone else have any better picks? And if so, why?